NCT06146270

Brief Summary

Identification of risk factors that cause a high probability of an unfavorable outcome in the postoperative period is an urgent problem. The creation of national databases (registries) makes it possible to maximally cover a certain patient population by identifying its characteristic risk predictors. As literature data show, existing registries differ in the criteria for inclusion in the study, in the characteristics of the populations studied, and there is often no common view on the classification of postoperative outcomes. Goal of a study is a creation of a Russian national calculator for the risk of postoperative complications and mortality. Two-level observational retrospective-prospective study was planned. Setting: National multicenter study of surgical inpatients. Patients: Adult patients undergoing elective and emergency surgery. Types of interventions: in obstetrics, in gynecology, on the breast, in urology and kidneys, in endocrine surgery, in maxillofacial surgery, in orthopedics and traumatology, on the lower floor of the abdominal cavity, on the liver and biliary tract, on the upper floor of the abdominal cavity cavities, in thoracic surgery, in vascular surgery, in neurosurgery, in cardiac surgery, in other areas (with mandatory specification). The study was organized by the Federation of Anesthesiologists and Reanimatologists of Russia. Primary (30-day mortality, 30-day complications) and secondary (hospital mortality, hospital complications, length of stay in anesthesiology, resuscitation and intensive care departments, length of hospital stay, multiple organ failure (2 or more points on the SOFA scale (Sequential)) Organ Failure Assessment), 90-day mortality, 90-day complications, intensive care after-effects syndrome, readmission, 1-year mortality) outcomes were determined. The required sample size and statistical analysis methods are described. The planned duration of the study is 2024-2028.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
162,000

participants targeted

Target at P75+ for all trials

Timeline
33mo left

Started Jan 2025

Longer than P75 for all trials

Geographic Reach
1 country

16 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress33%
Jan 2025Jan 2029

First Submitted

Initial submission to the registry

November 18, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 24, 2023

Completed
1.1 years until next milestone

Study Start

First participant enrolled

January 9, 2025

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2028

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2029

Last Updated

April 4, 2025

Status Verified

April 1, 2025

Enrollment Period

4 years

First QC Date

November 18, 2023

Last Update Submit

April 1, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Postoperative mortality

    Incidence of postoperative death defined as any death occurring during and up to 30 days after surgery

    up to 30 days after surgery

  • Postoperative complications

    Incidence of the following complications with severity due to Clavien-Dindo classification: Arrhythmia Cardiac arrest Cardiogenic pulmonary edema Deep vein thrombosis Myocardial infarction Myocardial damage after non-cardiac operations Pulmonary embolism Postoperative transfusion Postoperative delirium Stroke ARDS Acute respiratory failure Pneumonia Pleural effusion Atelectasis Respiratory infection Bronchospasm Pneumothorax Aspiration pneumonitis Reintubation Renal injury Infection without a specific source Laboratory confirmed bacteremia Superficial wound infection Deep wound infection Postoperative infection Urinary tract infection Sepsis Septic shock Gastrointestinal bleeding Paralytic ileus Postoperative bleeding Anastomotic leakage Dehiscence of wound Other Malignant hyperthermia Anaphylaxis Anaphylactic shock Fat embolism

    up to 30 days after surgery

Secondary Outcomes (8)

  • Length of stay in the ICU

    up to 30 days after surgery

  • Length of hospital stay

    up to 30 days after surgery

  • Multiple organ failure (2 or more points on the SOFA (Sequential Organ Failure Assessment) scale)

    up to 30 days after surgery

  • 90-days mortality

    up to 90 days after surgery

  • 90-days postoperative complications

    up to 90 days after surgery

  • +3 more secondary outcomes

Study Arms (2)

Cohort A

A cohort in which the incidence of the primary outcomes in the study population will be assessed.

Cohort B

A cohort in which risk factors for primary outcomes will be identified, and a risk calculator for their development will be developed and validated

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult patients undergoing surgery in various areas of surgery

You may qualify if:

  • Adult patients (age 18 years and older) undergoing elective surgery:
  • In obstetrics
  • In gynecology
  • Breast
  • In urology and kidneys
  • In endocrine surgery
  • In maxillofacial surgery
  • In orthopedics and traumatology
  • On the lower abdominal cavity
  • On the liver and biliary tract
  • On the upper abdominal cavity
  • In thoracic surgery
  • In vascular surgery
  • In neurosurgery
  • In cardiac surgery
  • +2 more criteria

You may not qualify if:

  • Lack of informed consent from the patient
  • Complications associated with the manipulations of an anesthesiologist
  • Interventions without the participation of an anesthesiologist-resuscitator
  • Incomplete checklists
  • Errors when filling checklists
  • Deviations from the Register protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (16)

The First City Clinical Hospital. n.a. E. E. Volosevich

Arkhangelsk, Russia

RECRUITING

Kuzbass Clinical Emergency Hospital named after M.A. Podgorbunsky

Kemerovo, Russia

RECRUITING

Regional clinical hospital №2

Krasnodar, 350012, Russia

RECRUITING

Kuban State Medical University

Krasnodar, 350063, Russia

RECRUITING

Krasnodar regional hospital №2 (Kuban State Medical University)

Krasnodar, Russia

NOT YET RECRUITING

Regional clinical hospital

Krasnoyarsk, Russia

RECRUITING

Federal research and clinical center of intensive care medicine and rehabilitology

Moscow, Russia

RECRUITING

Loginov Moscow Clinical Scientific Center

Moscow, Russia

NOT YET RECRUITING

Military Medical Academy

Moscow, Russia

NOT YET RECRUITING

Moscow cancer research Institute named after P. A. Herzen

Moscow, Russia

RECRUITING

Moscow Regional Research and Clinical Institute, Moscow, Russia

Moscow, Russia

NOT YET RECRUITING

Moscow regional research clinical Institute named after M. F. Vladimirsky

Moscow, Russia

RECRUITING

Orenburg City N.I. Pirogov Clinical Hospital

Orenburg, Russia

RECRUITING

North-Western State Medical University named after Ilya I. Mechnikov,

Saint Petersburg, Russia

NOT YET RECRUITING

Regional clinical hospital №2

Vladivostok, Russia

RECRUITING

Clinical city hospital № 40

Yekaterinburg, Russia

RECRUITING

Study Officials

  • Igor Zabolotskikh, MD

    Kuban State Medical University

    STUDY CHAIR
  • Nikita Trembach, MD

    Kuban State Medical University

    STUDY DIRECTOR
  • Andrey Belkin, MD

    Clinical Institute of Brain

    STUDY DIRECTOR
  • Evgeniy Grigiriev, MD

    Research Institute for Complex Issues of Cardiovascular Diseases

    STUDY DIRECTOR
  • Alexei Gritsan, MD

    Voino-Yasenetsky Krasnoyarsk State Medical University

    STUDY DIRECTOR
  • Pavel Dunts, PhD

    Pacific State Medical University

    STUDY DIRECTOR
  • Vadim Ershov, MD

    Orenburg State Medical University

    STUDY DIRECTOR
  • Mikhail Kirov, MD

    Northern State Medical University

    STUDY DIRECTOR
  • Artem Kuzovlev, MD

    Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

    STUDY DIRECTOR
  • Alexandr Kulikov, MD

    Ural State Medical University

    STUDY DIRECTOR
  • Alexey Ovezov, MD

    Moscow Regional Research and Clinical Institute

    STUDY DIRECTOR
  • Denis Protsenko, MD

    Pirogov Russian National Research Medical University

    STUDY DIRECTOR
  • Valeriy Subbotin, MD

    Loginov Moscow Clinical Scientific Center

    STUDY DIRECTOR
  • Victoria Khoronenko, MD

    P. A. Hertsen Moscow Oncology Research Center

    STUDY DIRECTOR
  • Efim Shifman, MD

    Moscow Regional Research and Clinical Institute, Moscow, Russia

    STUDY DIRECTOR
  • Alexey Shchegolev, MD

    Military Medical Academy, Bulgaria

    STUDY DIRECTOR
  • Konstantin Lebedinskii, MD

    North-Western State Medical University named after Ilya I. Mechnikov

    STUDY DIRECTOR

Central Study Contacts

Igor Zabolotskikh, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 18, 2023

First Posted

November 24, 2023

Study Start

January 9, 2025

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

January 31, 2029

Last Updated

April 4, 2025

Record last verified: 2025-04

Locations